Attovia Therapeutics ATTO
$15.10 −$0.48 (-3.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.10 0.00%
Open$15.40
Prev close$15.58
Day range$14.80 – $15.46
Volume372.2K
Market cap$690.26M
P/E (TTM)–
Dividend yield–
ATTO Stock News
Headlines matching Attovia Therapeutics or the ATTO ticker, most recent first.
- LifeSci Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
- Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $30
- Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
- Morgan Stanley Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $39
- Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO)
- RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
- U.S. Stocks Move | Biotech Company Attovia Therapeutics (ATTO.US) Debuts on Nasdaq, Closing Up 28.82% on First Trading Day
- LifeSci Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
- RBC Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
- Morgan Stanley Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $39
- Citi Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $30
- Goldman Sachs-backed immunotherapy startup Attovia (ATTO.US) files for Nasdaq listing: aiming to raise up to $212.5 million, becoming the latest addition to the biotech IPO boom Positive
- Attovia Says Phase 1b ATTO-1310 Gave 82% Of Chronic Itch Patients 4-Point Relief At Week 12 Vs. 22% On Placebo; Atopic Dermatitis Itch Response 44% Vs. 75% Placebo
- RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
- Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Raises Target Price to $34 Positive
No comments yet — be the first to weigh in on ATTO.
Sign in to join the discussion.